Abcuro raises $66.0M (Aug 2026)
Find the investors funding Health rounds
326,000+ verified VCs, angels and family offices — direct emails, check sizes and stage filters.
Abcuro Adds $66M to Try Again in Rare Inflammatory Disorder With No Approved Drugs - MedCity News
Abcuro is a biotechnology company focused on developing therapies for rare inflammatory disorders. The company aims to address unmet medical needs in conditions that currently lack approved treatments, making their work particularly significant in the healthcare landscape.
Abcuro Adds $66M to Try Again in Rare Inflammatory Disorder With No Approved Drugs MedCity News
| Sep 02, 2026 | Thyme Care | $125.0M | Series E | United States |
| Sep 02, 2026 | DocPharma | $2.0M | Pre-Series A | India |
| Sep 02, 2026 | GonGlobal | $1.2M | Seed | Australia |
| Sep 01, 2026 | Norbert Health | $14.0M | Series A | United States |
Find the investors behind rounds like this one
You just read who funded Abcuro. The same database has the investors behind every other round — with verified emails, check sizes and the stages they actually write at.
Free account: 5 investor contact unlocks a month, no card required.